A NEW ERA OF VACCINES

The Novavax COVID-19 Vaccine, Adjuvanted is now available in
the U.S. under Emergency Use Authorization for primary vaccination
for individuals 12+, and as a first booster dose for adults

See conditions of use

Latest press release on vaccine candidates

COVID-19 vaccine research updates

Novavax COVID-19 vaccine (recombinant, adjuvanted) is now conditionally authorized in several regions

Novavax information for:

NEWS & MEDIA

Novavax Announces Launch of Global Vaccine Education Programs

We focus on this so you can focus on that
NEWS & MEDIA

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

Novavax's Investor Hub

Visit our Investor Hub to access investor resources and information on upcoming and past events. Sign up to receive notifications for investor updates, such as upcoming events and webcasts, daily closing stock price, SEC filings, and press releases.

Latest quarterly earnings
Latest investor presentation
2022 annual report
NASDAQ:NVAX
Loading data...

Explore current opportunities in:

Insights

Why do we need vaccine booster injections?

Science & technology

Our pipeline—creating tomorrow's vaccines today

Who we are

Novavax is powered by global collaborations